Developer docs
API playgroundTry for free, no card

Search company profiles

MetaVia

Full company profile

uuid00042em

Namestring
MetaVia
Legal namestring
MetaVia Inc.
Websiteurl
metaviatx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

MetaVia is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for cardiometabolic diseases, specifically obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's pipeline centers on two core assets: DA-1726, a long-acting dual GLP-1/glucagon receptor agonist oxyntomodulin peptide analog designed as a once-weekly injection for obesity, which demonstrated 9.1% mean body weight reduction at 48mg by Day 54 in a Phase 1 trial; and vanoglipel (DA-1241), an oral GPR119 agonist that has shown 10.2% liver fibrosis reduction versus 10.1% increase for placebo in a Phase 2a MASH trial. Both programs are built on exclusive licensing arrangements with Dong-A ST Co., Ltd., MetaVia's largest investor and strategic partner, which provides R&D, scientific, and CMC manufacturing support. The company also maintains legacy assets (NB-01, NB-02, ANA001, Gemcabene) that are being evaluated for out-licensing, and has an AI-based drug discovery collaboration with Syntekabio using the DeepMatcher platform for indication prioritization.

MetaVia operates a pre-revenue business model with no current product sales or disclosed pricing. Its revenue mechanics are entirely prospective, anticipated to flow from future commercialization of DA-1726 and vanoglipel through traditional pharmaceutical distribution channels, potential licensing deals, or co-promotion partnerships upon FDA approval. The company currently monetizes only via public equity offerings — completing $10 million in 2025 and $9.3 million in 2026 — to fund ongoing clinical development, and reported a $3.8 million net loss in Q1 2026 with cash runway extending only into Q4 2026. Formerly known as NeuroBo Pharmaceuticals Inc., MetaVia executed a strategic rebrand, a 1-for-11 reverse stock split, and refocused the business around cardiometabolic disease. The company trades on NASDAQ under ticker MTVA (previously NRBO under the NeuroBo identity) with a market capitalization of approximately $19.17 million as of January 2026, reflecting its early-stage status and small public float.

The company's go-to-market upon approval will leverage enterprise pharmaceutical partnerships rather than direct sales, given its 11-50 employee headcount and reliance on Dong-A ST for CMC and development infrastructure. Customer segments are defined by therapeutic indication rather than commercial buyer: obesity patients requiring interventional weight management, MASH patients with progressive fatty liver disease, and secondarily type 2 diabetes and dyslipidemia patients. AI capability is limited to a single third-party partnership for target validation rather than embedded in core R&D operations. Overall, MetaVia represents a small-cap, capital-constrained clinical biotech whose strategic value depends on successful advancement of two early-stage drug candidates and eventual partnership or licensing outcomes.

Short descriptiontext

MetaVia is a clinical-stage biotechnology company developing DA-1726 (a dual GLP-1/glucagon agonist for obesity) and vanoglipel (a GPR119 agonist for MASH), operating pre-revenue with exclusive licensing from strategic partner Dong-A ST and trading on NASDAQ under ticker MTVA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, cardiometabolic therapeutics, obesity drug development, MASH treatment, peptide therapeutics
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAKAEAB
Hepatology & Liver Disease
Product category
Cardiometabolic Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Anticipated future revenue from commercialization of drug candidates DA-1726 for obesity and vanoglipel for MASH upon regulatory approval. May pursue licensing deals or co-promotion partnerships.

metaviatx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MetaVia is a clinical-stage biotechnology company developing multimodal disease-modifying therapies for cardiometabolic diseases. Its lead clinical assets are DA-1726, a once-weekly injectable dual GLP-1/glucagon receptor agonist (oxyntomodulin peptide analog) for obesity, and Vanoglipel (DA-1241), an oral GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company also retains legacy assets (NB-01, NB-02, ANA001, Gemcabene) being evaluated for strategic out-licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 9.1% mean body weight reduction at 48 mg dose by Day 54 in obese but otherwise healthy adults
+4 more records
Product overview1 text field

MetaVia is a clinical-stage biotechnology company developing two primary drug candidates for cardiometabolic diseases: DA-1726, a GLP1R/GCGR dual agonist (once-weekly injection for obesity), and vanoglipel (DA-1241), a GPR119 agonist (oral treatment for MASH). The company also maintains legacy assets including NB-01 (diabetic neuropathy), NB-02 (Alzheimer's disease), ANA001 (COVID-19 antiviral), and Gemcabene (dyslipidemia), which are being assessed for strategic out-licensing opportunities.

Product and service1 record
1DA-1726
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Dong-A ST Research Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Preclinical combination therapy studies for vanoglipel conducted in partnership with Dong-A ST Research Center, demonstrating synergistic hepatoprotective and weight-loss effects when combined with resmetirom (MASH model) and enhanced glycemic control when combined with metformin (T2D model).

prnewswire.com
2Dong-A ST Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-13
Description

MetaVia has a strategic partnership and licensing agreement with Dong-A ST Co., Ltd., part of the Dong-A Socio Group established in 1932 and based in South Korea. Dong-A ST is MetaVia's largest investor and provides full support including access to R&D, scientific, and CMC (manufacturing) expertise. The licensing agreement covers DA-1726 and related compounds with exclusive rights for global development and commercialization.

stocktitan.net
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-02-04
Description

AI-based drug discovery collaboration using Syntekabio's DeepMatcher platform to confirm therapeutic targets for vanoglipel (DA-1241). The partnership identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted therapeutic areas for GPR119 agonism. The company plans to continue using Syntekabio's AI platform to explore additional indications and optimize the drug's therapeutic profile.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage French biotech developing lanifibranor for MASH. Directly comparable pre-commercial MASH player; both are pursuing oral therapies for the same cardiometabolic liver indication.

TypeDirect peer
Description

Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH with strong Phase 2b fibrosis data. Competes with MetaVia's vanoglipel in the MASH space and is similarly sized pre-commercial.

TypeDirect peer
Description

Clinical-stage biotech developing TERN-601 (oral GLP-1 agonist for obesity) and MASH assets. Comparable as a small-cap dual-indication cardiometabolic company pursuing oral obesity therapy.

TypeBroad incumbent
Description

Developer of tirzepatide (Zepbound/Mounjaro) and the next-generation retatrutide and oral orforglipron. The dominant commercial benchmark for DA-1726's preclinical superiority claims; defines the obesity competitive landscape MetaVia must navigate.

TypeBroad incumbent
Description

Developer of semaglutide (Wegovy/Ozempic), the current GLP-1 standard of care that DA-1726 is being benchmarked against in preclinical models. Represents the entrenched obesity market leader MetaVia aims to differentiate from.

TypeDirect peer
Description

Clinical-stage biotech developing pegozafermin for MASH. Directly comparable as a small-cap MASH-focused company with similar Phase 2/3-stage assets competing for the same patient population.

TypeDirect peer
Description

Clinical-stage biotech developing oral GLP-1 agonists (GSBR-1290) for obesity and related cardiometabolic conditions. Comparable mechanism (oral incretin) and target indication to MetaVia's DA-1726 program.

TypeDirect peer
Description

Developer of Rezdiffra (resmetirom), the first FDA-approved MASH therapy. Directly comparable as a MASH-focused biotech; MetaVia's vanoglipel + resmetirom combination work targets the same indication.

TypeDirect peer
Description

Clinical-stage biotech developing VK2735 (oral/dual GLP-1/GIP agonist for obesity) and VK2809 (MASH). Directly comparable to MetaVia as a small-cap dual-indication cardiometabolic biotech with similar market cap and pipeline focus.

TypeEmerging player
Description

Clinical-stage biotech developing survodutide (dual GLP-1/glucagon agonist) in partnership with Boehringer Ingelheim for obesity and MASH. Highly comparable mechanism (dual GLP-1/glucagon) and indication overlap with MetaVia's DA-1726.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MetaVia

Cardiometabolic Therapeuticsmetaviatx.com

MetaVia is a clinical-stage biotechnology company developing DA-1726 (a dual GLP-1/glucagon agonist for obesity) and vanoglipel (a GPR119 agonist for MASH), operating pre-revenue with exclusive licensing from strategic partner Dong-A ST and trading on NASDAQ under ticker MTVA.

What MetaVia does

MetaVia is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for cardiometabolic diseases, specifically obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's pipeline centers on two core assets: DA-1726, a long-acting dual GLP-1/glucagon receptor agonist oxyntomodulin peptide analog designed as a once-weekly injection for obesity, which demonstrated 9.1% mean body weight reduction at 48mg by Day 54 in a Phase 1 trial; and vanoglipel (DA-1241), an oral GPR119 agonist that has shown 10.2% liver fibrosis reduction versus 10.1% increase for placebo in a Phase 2a MASH trial. Both programs are built on exclusive licensing arrangements with Dong-A ST Co., Ltd., MetaVia's largest investor and strategic partner, which provides R&D, scientific, and CMC manufacturing support. The company also maintains legacy assets (NB-01, NB-02, ANA001, Gemcabene) that are being evaluated for out-licensing, and has an AI-based drug discovery collaboration with Syntekabio using the DeepMatcher platform for indication prioritization.

MetaVia operates a pre-revenue business model with no current product sales or disclosed pricing. Its revenue mechanics are entirely prospective, anticipated to flow from future commercialization of DA-1726 and vanoglipel through traditional pharmaceutical distribution channels, potential licensing deals, or co-promotion partnerships upon FDA approval. The company currently monetizes only via public equity offerings — completing $10 million in 2025 and $9.3 million in 2026 — to fund ongoing clinical development, and reported a $3.8 million net loss in Q1 2026 with cash runway extending only into Q4 2026. Formerly known as NeuroBo Pharmaceuticals Inc., MetaVia executed a strategic rebrand, a 1-for-11 reverse stock split, and refocused the business around cardiometabolic disease. The company trades on NASDAQ under ticker MTVA (previously NRBO under the NeuroBo identity) with a market capitalization of approximately $19.17 million as of January 2026, reflecting its early-stage status and small public float.

The company's go-to-market upon approval will leverage enterprise pharmaceutical partnerships rather than direct sales, given its 11-50 employee headcount and reliance on Dong-A ST for CMC and development infrastructure. Customer segments are defined by therapeutic indication rather than commercial buyer: obesity patients requiring interventional weight management, MASH patients with progressive fatty liver disease, and secondarily type 2 diabetes and dyslipidemia patients. AI capability is limited to a single third-party partnership for target validation rather than embedded in core R&D operations. Overall, MetaVia represents a small-cap, capital-constrained clinical biotech whose strategic value depends on successful advancement of two early-stage drug candidates and eventual partnership or licensing outcomes.

MetaVia firmographics

Firmographics
Name
MetaVia
Legal name
MetaVia Inc.
Website
https://metaviatx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
MetaVia is a clinical-stage biotechnology company developing DA-1726 (a dual GLP-1/glucagon agonist for obesity) and vanoglipel (a GPR119 agonist for MASH), operating pre-revenue with exclusive licensing from strategic partner Dong-A ST and trading on NASDAQ under ticker MTVA.
Ownership category
akta.pro rank

MetaVia industry classification

Industry
Product category
Cardiometabolic Therapeutics
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAKAEAB
Hepatology & Liver Disease

Keywords

  • Clinical-stage biotechnology
  • Cardiometabolic therapeutics
  • Obesity drug development
  • MASH treatment
  • Peptide therapeutics

Where MetaVia is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MetaVia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Anticipated future revenue from commercialization of drug candidates DA-1726 for obesity and vanoglipel for MASH upon regulatory approval. May pursue licensing deals or co-promotion partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

MetaVia product offering

Product offering

Core offering

MetaVia is a clinical-stage biotechnology company developing multimodal disease-modifying therapies for cardiometabolic diseases. Its lead clinical assets are DA-1726, a once-weekly injectable dual GLP-1/glucagon receptor agonist (oxyntomodulin peptide analog) for obesity, and Vanoglipel (DA-1241), an oral GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company also retains legacy assets (NB-01, NB-02, ANA001, Gemcabene) being evaluated for strategic out-licensing.

Product overview

MetaVia is a clinical-stage biotechnology company developing two primary drug candidates for cardiometabolic diseases: DA-1726, a GLP1R/GCGR dual agonist (once-weekly injection for obesity), and vanoglipel (DA-1241), a GPR119 agonist (oral treatment for MASH). The company also maintains legacy assets including NB-01 (diabetic neuropathy), NB-02 (Alzheimer's disease), ANA001 (COVID-19 antiviral), and Gemcabene (dyslipidemia), which are being assessed for strategic out-licensing opportunities.

Differentiator

Problem solved

Functional benefit

Products and services

  • DA-1726

Quantifiable outcome

  • 9.1% mean body weight reduction at 48 mg dose by Day 54 in obese but otherwise healthy adults
  • +4 more outcomes

Companies that use MetaVia

Customer profile

Segments3 records

Ideal customer profiles2 records

MetaVia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MetaVia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Dong-A ST Research CentercoreStrategic or Co-development Partner · 18 May 2026Preclinical combination therapy studies for vanoglipel conducted in partnership with Dong-A ST Research Center, demonstrating synergistic hepatoprotective and weight-loss effects when combined with resmetirom (MASH model) and enhanced glycemic control when combined with metformin (T2D model).
  • Dong-A ST Co., Ltd.coreStrategic or Co-development Partner · 13 February 2026MetaVia has a strategic partnership and licensing agreement with Dong-A ST Co., Ltd., part of the Dong-A Socio Group established in 1932 and based in South Korea. Dong-A ST is MetaVia's largest investor and provides full support including access to R&D, scientific, and CMC (manufacturing) expertise. The licensing agreement covers DA-1726 and related compounds with exclusive rights for global development and commercialization.
  • SyntekabiosupportingTechnology or Integration · 4 February 2026AI-based drug discovery collaboration using Syntekabio's DeepMatcher platform to confirm therapeutic targets for vanoglipel (DA-1241). The partnership identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted therapeutic areas for GPR119 agonism. The company plans to continue using Syntekabio's AI platform to explore additional indications and optimize the drug's therapeutic profile.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

MetaVia competitors and assessment

Company assessment

Direct peers

  • Inventiva: Clinical-stage French biotech developing lanifibranor for MASH. Directly comparable pre-commercial MASH player; both are pursuing oral therapies for the same cardiometabolic liver indication.
  • Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH with strong Phase 2b fibrosis data. Competes with MetaVia's vanoglipel in the MASH space and is similarly sized pre-commercial.
  • Terns Pharmaceuticals: Clinical-stage biotech developing TERN-601 (oral GLP-1 agonist for obesity) and MASH assets. Comparable as a small-cap dual-indication cardiometabolic company pursuing oral obesity therapy.
  • 89bio: Clinical-stage biotech developing pegozafermin for MASH. Directly comparable as a small-cap MASH-focused company with similar Phase 2/3-stage assets competing for the same patient population.
  • Structure Therapeutics: Clinical-stage biotech developing oral GLP-1 agonists (GSBR-1290) for obesity and related cardiometabolic conditions. Comparable mechanism (oral incretin) and target indication to MetaVia's DA-1726 program.
  • Madrigal Pharmaceuticals: Developer of Rezdiffra (resmetirom), the first FDA-approved MASH therapy. Directly comparable as a MASH-focused biotech; MetaVia's vanoglipel + resmetirom combination work targets the same indication.
  • Viking Therapeutics: Clinical-stage biotech developing VK2735 (oral/dual GLP-1/GIP agonist for obesity) and VK2809 (MASH). Directly comparable to MetaVia as a small-cap dual-indication cardiometabolic biotech with similar market cap and pipeline focus.

Broad incumbents

  • Eli Lilly: Developer of tirzepatide (Zepbound/Mounjaro) and the next-generation retatrutide and oral orforglipron. The dominant commercial benchmark for DA-1726's preclinical superiority claims; defines the obesity competitive landscape MetaVia must navigate.
  • Novo Nordisk: Developer of semaglutide (Wegovy/Ozempic), the current GLP-1 standard of care that DA-1726 is being benchmarked against in preclinical models. Represents the entrenched obesity market leader MetaVia aims to differentiate from.

Emerging players

  • Zealand Pharma: Clinical-stage biotech developing survodutide (dual GLP-1/glucagon agonist) in partnership with Boehringer Ingelheim for obesity and MASH. Highly comparable mechanism (dual GLP-1/glucagon) and indication overlap with MetaVia's DA-1726.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

MetaVia social profiles

Digital presence

MetaVia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MetaVia leadership team

Management profile

Number of profiles

Profiles17 records

MetaVia funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MetaVia M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MetaVia

What does MetaVia do?

MetaVia is a clinical-stage biotechnology company developing multimodal disease-modifying therapies for cardiometabolic diseases. Its lead clinical assets are DA-1726, a once-weekly injectable dual GLP-1/glucagon receptor agonist (oxyntomodulin peptide analog) for obesity, and Vanoglipel (DA-1241), an oral GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company also retains legacy assets (NB-01, NB-02, ANA001, Gemcabene) being evaluated for strategic out-licensing.

Is MetaVia a public or private company?

MetaVia is a public company. It is classified as public and is currently operating.

When was MetaVia founded?

MetaVia was founded in 2017. It employs 11 to 50 people.

Where is MetaVia based?

MetaVia is headquartered in Cambridge, United States, in the North America region.

How does MetaVia make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are MetaVia's main competitors?

Direct peers on record are Inventiva, Akero Therapeutics, Terns Pharmaceuticals, 89bio, Structure Therapeutics, Madrigal Pharmaceuticals and Viking Therapeutics. Broad incumbents are Eli Lilly and Novo Nordisk. Zealand Pharma is listed as an emerging player.

Does MetaVia have an API?

No public API is recorded for MetaVia.

What industry is MetaVia in?

MetaVia's product category is Cardiometabolic Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeMetaVia Reports $4.6 Million Third Quarter Loss and DA-1726 Data | MTVA Stock NewsMetaVia reported a Q3 2026 net loss of $4.6 million, or $0.69 per share, with $8.8 million in cash. The company's DA-1726 showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss at Day 109. Full Phase 1 data is expected in Q1 2027, with a Phase 2 study planned for late 2027.Longevity.TechnologyMetaVia shows uric acid reduction with DA-1726 in Phase 1MetaVia announced interim Part 3B data from its 16-week, randomized, placebo-controlled Phase 1 study in adults with obesity. The study showed a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid at Day 109 (p<0.001) with once-weekly DA-1726.Longevity.TechnologyMetaVia’s DA-1726 shows weight and liver fat reductionsMetaVia announced an abstract on DA-1726, a dual oxyntomodulin analogue, accepted for ObesityWeek 2026. A Phase 1 Part 3B interim analysis showed a 13.5% placebo-adjusted weight reduction and 68% liver fat reduction. The company plans a Phase 2 study in MetALD and ALD to begin in 2027.Longevity.TechnologyMetavia interim data show 68% liver fat reductionMetavia released interim Part 3B results from its Phase 1 trial of DA-1726, a once-weekly oxyntomodulin analog, showing a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted body weight reduction after 16 weeks. The MRI substudy included 12 treated and four placebo participants, with 10 of 12 treated participants achieving at least a 30% relative liver fat reduction. Full data are expected in Q1 2027, with a Phase 2 study planned for 2027.STATUp and down the ladder: The latest comings and goingsMetaVia hired Sarah Browne as chief medical officer. She previously served as clinical development consultant to Soufflé Therapeutics and vice president of clinical development at Altimmune. The article is exclusive to STAT+ subscribers.BusinesskoreaMetavia Reports DA-1726 Cuts Liver FatMetavia reported interim results from its Phase 1 trial of DA-1726, showing a 68% liver fat reduction and 13.5% weight loss versus placebo after 16 weeks. The company plans to expand indications to MetALD and ALD, with full data in Q1 2027 and a Phase 2 trial in H2 2027.Businesskorea메타비아, DA-1726, 간 지방 68%·체중 13.5% 감소 확인Metavia presented interim results of DA-1726's phase 1 Part 3B trial, showing 68% liver fat reduction and 13.5% weight loss versus placebo. The drug, an oxyntomodulin analog, also improved HbA1c and body composition. Metavia plans to expand indications to alcohol-related liver disease and begin phase 2 trials in 2027.TradingViewMetaVia Reports 68% Placebo-Adjusted Liver Fat Reduction for DA-1726MetaVia reported interim Phase 1 data showing DA-1726 reduced liver fat by 68% versus placebo after 16 weeks. The drug also delivered 13.5% placebo-adjusted weight loss and a 0.24 percentage-point HbA1c reduction. MetaVia expects full Part 3A and 3B data in Q1 2027 and targets a 48-week Phase 2 study in up to 150 MetALD and ALD patients in H2 2027.FierceBiotechMetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver diseaseMetaVia reported in a phase 1 trial that its GLP-1/glucagon agonist DA-1726 reduced liver fat by 68% and body weight by 13.5% in 15 obese adults. The company plans a phase 2 trial in alcohol-associated liver disease next year, targeting an uncongested market segment.Business & FinancialGlucagon-Like Peptide Agonist Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead The Charge In Pioneering New Treatments DelveinsightDelveInsight's report on the glucagon-like peptide agonist pipeline covers 45+ companies and 50+ drugs, including Phase I data for MetaVia's DA-1726 and Viking Therapeutics' SUNRISE Phase III. It also highlights Biomea Fusion's BMF-650 results showing 1.5-3.2% weight loss. The report assesses therapies by stage, route, and molecule type.